More recently, lncRNA SOX2OT has been shown to be a prognostic marker for GBM patients and confer chemoresistance to TMZ by regulating SOX2 expression, thereby driving Wnt5a/β-catenin pathway [29]. This evidence concerns the gene SOX2 and glioblastoma.